Combining a glycolysis‑related prognostic model based on scRNA‑Seq with experimental verification identifies ZFP41 as a potential prognostic biomarker for HCC

Teng,Yu; Xu,Jianrong; Wang,Yaoqun; Wen,Ningyuan; Ye,Hui; Li,Bei

doi:10.3892/mmr.2024.13203

Combining a glycolysis‑related prognostic model based on scRNA‑Seq with experimental verification identifies ZFP41 as a potential prognostic biomarker for HCC

Authors:
- Yu Teng
- Jianrong Xu
- Yaoqun Wang
- Ningyuan Wen
- Hui Ye
- Bei Li
View Affiliations

Affiliations: West China School of Medicine, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Research Center for Biliary Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: March 19, 2024 https://doi.org/10.3892/mmr.2024.13203
Article Number: 78
Copyright: © Teng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy with a poor prognosis, and its heterogeneity affects the response to clinical treatments. Glycolysis is highly associated with HCC therapy and prognosis. The present study aimed to identify a novel biomarker for HCC by exploring the heterogeneity of glycolysis in HCC. The intersection of both marker genes of glycolysis‑related cell clusters from single‑cell RNA sequencing analysis and mRNA data of liver HCC from The Cancer Genome Atlas were used to construct a prognostic model through Cox proportional hazard regression and the least absolute shrinkage and selection operator Cox regression. Data from the International Cancer Genome Consortium were used to validate the results of the analysis. Immune status analysis was then conducted. A significant gene in the prognostic model was identified as a potential biomarker and was verified through in vitro experiments. The results revealed that the glycolysis‑related prognostic model divided patients with HCC into high‑ and low‑risk groups. A nomogram combining the model and clinical features exhibited accurate predictive ability, with an area under the curve of 0.763 at 3 years. The high‑risk group exhibited a higher expression of checkpoint genes and lower tumor immune dysfunction and exclusion scores, suggesting that this group may be more likely to benefit from immunotherapy. The tumor tissues had a higher zinc finger protein (ZFP)41 mRNA and protein expression compared with the adjacent tissues. In vitro analyses revealed that ZFP41 played a crucial role in cell viability, proliferation, migration, invasion and glycolysis. On the whole, the present study demonstrates that the glycolysis‑related prognostic gene, ZFP41, is a potential prognostic biomarker and therapeutic target, and may play a crucial role in glycolysis and malignancy in HCC.

View Figures

View References

1	Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021. View Article : Google Scholar : PubMed/NCBI
2	McGlynn KA, Petrick JL and El-Serag HB: Epidemiology of hepatocellular carcinoma. Hepatology. 73 (Suppl 1):S4–S13. 2021. View Article : Google Scholar
3	Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ and Villanueva A: Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 3:386–401. 2022. View Article : Google Scholar : PubMed/NCBI
4	Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, Dai W and Guo C: Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res. 39:1262020. View Article : Google Scholar : PubMed/NCBI
5	Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S, Hao H and Xiong J: Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B. 12:558–580. 2022. View Article : Google Scholar : PubMed/NCBI
6	Zhang Y, Zhai Z, Duan J, Wang X, Zhong J, Wu L, Li A, Cao M, Wu Y, Shi H, et al: Lactate: The mediator of metabolism and immunosuppression. Front Endocrinol (Lausanne). 13:9014952022. View Article : Google Scholar : PubMed/NCBI
7	Zhang QY, Ho DW, Tsui YM and Ng IO: Single-cell transcriptomics of liver cancer: Hype or insights? Cell Mol Gastroenterol Hepatol. 14:513–525. 2022. View Article : Google Scholar : PubMed/NCBI
8	Aliya S, Lee H, Alhammadi M, Umapathi R and Huh YS: An overview on single-cell technology for hepatocellular carcinoma diagnosis. Int J Mol Sci. 23:14022022. View Article : Google Scholar : PubMed/NCBI
9	Zhang Y, Wang D, Peng M, Tang L, Ouyang J, Xiong F, Guo C, Tang Y, Zhou Y, Liao Q, et al: Single-cell RNA sequencing in cancer research. J Exp Clin Cancer Res. 40:812021. View Article : Google Scholar : PubMed/NCBI
10	Lei Y, Tang R, Xu J, Wang W, Zhang B, Liu J, Yu X and Shi S: Applications of single-cell sequencing in cancer research: Progress and perspectives. J Hematol Oncol. 14:912021. View Article : Google Scholar : PubMed/NCBI
11	Martens JH and Stunnenberg HG: BLUEPRINT: Mapping human blood cell epigenomes. Haematologica. 98:1487–1489. 2013. View Article : Google Scholar : PubMed/NCBI
12	ENCODE Project Consortium, . An integrated encyclopedia of DNA elements in the human genome. Nature. 489:57–74. 2012. View Article : Google Scholar : PubMed/NCBI
13	Mabbott NA, Baillie JK, Brown H, Freeman TC and Hume DA: An expression atlas of human primary cells: Inference of gene function from coexpression networks. BMC Genomics. 14:6322013. View Article : Google Scholar : PubMed/NCBI
14	Schmiedel BJ, Singh D, Madrigal A, Valdovino-Gonzalez AG, White BM, Zapardiel-Gonzalo J, Ha B, Altay G, Greenbaum JA, McVicker G, et al: Impact of genetic polymorphisms on human immune cell gene expression. Cell. 175:1701–15.e16. 2018. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM and Pawlik TM: Management of hepatocellular carcinoma: A review. JAMA Surg. 158:410–420. 2023. View Article : Google Scholar : PubMed/NCBI
17	Wen N, Cai Y, Li F, Ye H, Tang W, Song P and Cheng N: The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 Update. Biosci Trends. 16:20–30. 2022. View Article : Google Scholar : PubMed/NCBI
18	Chidambaranathan-Reghupaty S, Fisher PB and Sarkar D: Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 149:1–61. 2021. View Article : Google Scholar : PubMed/NCBI
19	Vogel A, Meyer T, Sapisochin G, Salem R and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362. 2022. View Article : Google Scholar : PubMed/NCBI
20	Zhang Q, Lou Y, Yang J, Wang J, Feng J, Zhao Y, Wang L, Huang X, Fu Q, Ye M, et al: Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut. 68:2019–2031. 2019. View Article : Google Scholar : PubMed/NCBI
21	Sperandio RC, Pestana RC, Miyamura BV and Kaseb AO: Hepatocellular carcinoma immunotherapy. Annu Rev Med. 73:267–278. 2022. View Article : Google Scholar : PubMed/NCBI
22	Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, Li Y and Jiang X: Immunotherapy for hepatocellular carcinoma: Current status and future prospects. Front Immunol. 12:7651012021. View Article : Google Scholar : PubMed/NCBI
23	Jiang Y, Han QJ and Zhang J: Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol. 25:3151–3167. 2019. View Article : Google Scholar : PubMed/NCBI
24	Chen L, Huang L, Gu Y, Cang W, Sun P and Xiang Y: Lactate-lactylation hands between metabolic reprogramming and immunosuppression. Int J Mol Sci. 23:119432022. View Article : Google Scholar : PubMed/NCBI
25	Ganapathy-Kanniappan S: Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunities. Biochim Biophys Acta Rev Cancer. 1868:212–220. 2017. View Article : Google Scholar : PubMed/NCBI
26	Ganapathy-Kanniappan S and Geschwind JF: Tumor glycolysis as a target for cancer therapy: Progress and prospects. Mol Cancer. 12:1522013. View Article : Google Scholar : PubMed/NCBI
27	Su X, Zhao L, Shi Y, Zhang R, Long Q, Bai S, Luo Q, Lin Y, Zou X, Ghazanfar S, et al: Clonal evolution in liver cancer at single-cell and single-variant resolution. J Hematol Oncol. 14:222021. View Article : Google Scholar : PubMed/NCBI
28	Li Y, Song Z, Han Q, Zhao H, Pan Z, Lei Z and Zhang J: Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis. Mol Oncol. 16:2861–2880. 2022. View Article : Google Scholar : PubMed/NCBI
29	Matsumoto K, Noda T, Kobayashi S, Sakano Y, Yokota Y, Iwagami Y, Yamada D, Tomimaru Y, Akita H, Gotoh K, et al: Inhibition of glycolytic activator PFKFB3 suppresses tumor growth and induces tumor vessel normalization in hepatocellular carcinoma. Cancer Lett. 500:29–40. 2021. View Article : Google Scholar : PubMed/NCBI
30	Chen DP, Ning WR, Jiang ZZ, Peng ZP, Zhu LY, Zhuang SM, Kuang DM, Zheng L and Wu Y: Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma. J Hepatol. 71:333–343. 2019. View Article : Google Scholar : PubMed/NCBI
31	Suthen S, Lim CJ, Nguyen PHD, Dutertre CA, Lai HLH, Wasser M, Chua C, Lim TKH, Leow WQ, Loh TJ, et al: Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC. Hepatology. 76:1329–1344. 2022. View Article : Google Scholar : PubMed/NCBI
32	Lu LG, Zhou ZL, Wang XY, Liu BY, Lu JY, Liu S, Zhang GB, Zhan MX and Chen Y: PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma. Gut. 71:2551–2560. 2022. View Article : Google Scholar : PubMed/NCBI
33	Cheng K, Cai N, Zhu J, Yang X, Liang H and Zhang W: Tumor-associated macrophages in liver cancer: From mechanisms to therapy. Cancer Commun (Lond). 42:1112–1140. 2022. View Article : Google Scholar : PubMed/NCBI
34	Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF and Sancho D: Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 20:7–24. 2020. View Article : Google Scholar : PubMed/NCBI
35	Xu F, Jin T, Zhu Y and Dai C: Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 37:1102018. View Article : Google Scholar : PubMed/NCBI
36	Huang CF, Huang CY, Yeh ML, Wang SC, Chen KY, Ko YM, Lin CC, Tsai YS, Tsai PC, Lin ZY, et al: Genetics variants and serum levels of MHC class I chain-related A in predicting hepatocellular carcinoma development in chronic hepatitis C patients post antiviral treatment. EBioMedicine. 15:81–89. 2017. View Article : Google Scholar : PubMed/NCBI
37	Sajid M, Liu L and Sun C: The dynamic role of NK cells in liver cancers: Role in HCC and HBV associated HCC and its therapeutic implications. Front Immunol. 13:8871862022. View Article : Google Scholar : PubMed/NCBI
38	Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, Lim KH, Weber A, Chow P, Chung A, et al: Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut. 66:342–351. 2017. View Article : Google Scholar : PubMed/NCBI
39	Dunn GP, Koebel CM and Schreiber RD: Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 6:836–848. 2006. View Article : Google Scholar : PubMed/NCBI
40	Donne R and Lujambio A: The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology. 77:1773–1796. 2023. View Article : Google Scholar : PubMed/NCBI
41	Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P and Liu XS: Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 12:212020. View Article : Google Scholar : PubMed/NCBI
42	Cappellesso F, Orban MP, Shirgaonkar N, Berardi E, Serneels J, Neveu MA, Di Molfetta D, Piccapane F, Caroppo R, Debellis L, et al: Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. Nat Cancer. 3:1464–1483. 2022. View Article : Google Scholar : PubMed/NCBI
43	Ganapathy-Kanniappan S: Taming tumor glycolysis and potential implications for immunotherapy. Front Oncol. 7:362017. View Article : Google Scholar : PubMed/NCBI
44	Gong Y, Ji P, Yang YS, Xie S, Yu TJ, Xiao Y, Jin ML, Ma D, Guo LW, Pei YC, et al: Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 33:51–64.e9. 2021. View Article : Google Scholar : PubMed/NCBI
45	Li X, Han M, Zhang H, Liu F, Pan Y, Zhu J, Liao Z, Chen X and Zhang B: Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma. Biomark Res. 10:22022. View Article : Google Scholar : PubMed/NCBI
46	Shen Y, Zhang Y, Xiong Y, Zhang Z, Zhang B, Li A, Zhang Z, Ding J, Du J and Che Y: Whole exome sequencing identifies genetic variants in Chinese Han pregnant women with venous thromboembolism. Thromb Res. 211:49–55. 2022. View Article : Google Scholar : PubMed/NCBI
47	Guo HJ, Wang LJ, Wang C, Guo DZ, Xu BH, Guo XQ and Li H: Identification of an Apis cerana zinc finger protein 41 gene and its involvement in the oxidative stress response. Arch Insect Biochem Physiol. 108:e218302021. View Article : Google Scholar : PubMed/NCBI
48	Jiang P, He S, Li Y and Xu Z: Identification of therapeutic and prognostic biomarkers of Lamin C (LAMC) family members in head and neck squamous cell carcinoma. Med Sci Monit. 26:e9257352020. View Article : Google Scholar : PubMed/NCBI
49	Yamada N, Yasui K, Dohi O, Gen Y, Tomie A, Kitaichi T, Iwai N, Mitsuyoshi H, Sumida Y, Moriguchi M, et al: Genome-wide DNA methylation analysis in hepatocellular carcinoma. Oncol Rep. 35:2228–2236. 2016. View Article : Google Scholar : PubMed/NCBI
50	Fu H, Gao H, Qi X, Zhao L, Wu D, Bai Y, Li H, Liu X, Hu J and Shao S: Aldolase A promotes proliferation and G₁/S transition via the EGFR/MAPK pathway in non-small cell lung cancer. Cancer Commun (Lond). 38:182018.PubMed/NCBI
51	Sun M, Li L, Niu Y, Wang Y, Yan Q, Xie F, Qiao Y, Song J, Sun H, Li Z, et al: PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism. Acta Pharm Sin B. 13:157–173. 2023. View Article : Google Scholar : PubMed/NCBI
52	Zhu Y, Jin L, Shi R, Li J, Wang Y, Zhang L, Liang CZ, Narayana VK, De Souza DP, Thorne RF, et al: The long noncoding RNA glycoLINC assembles a lower glycolytic metabolon to promote glycolysis. Mol Cell. 82:542–554.e6. 2022. View Article : Google Scholar : PubMed/NCBI
53	Pan M, Luo M, Liu L, Chen Y, Cheng Z, Wang K, Huang L, Tang N, Qiu J, Huang A and Xia J: EGR1 suppresses HCC growth and aerobic glycolysis by transcriptionally downregulating PFKL. J Exp Clin Cancer Res. 43:352024. View Article : Google Scholar : PubMed/NCBI
54	Zheng C, Yu X, Liang Y, Zhu Y, He Y, Liao L, Wang D, Yang Y, Yin X, Li A, et al: Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK/FOXO3a/BIM-dependent manner. Acta Pharm Sin B. 12:1271–1287. 2022. View Article : Google Scholar : PubMed/NCBI
55	Bian Z, Yang F, Xu P, Gao G, Yang C, Cao Y, Yao S, Wang X, Yin Y, Fei B and Huang Z: LINC01852 inhibits the tumorigenesis and chemoresistance in colorectal cancer by suppressing SRSF5-mediated alternative splicing of PKM. Mol Cancer. 23:232024. View Article : Google Scholar : PubMed/NCBI
56	Chen Z, He Q, Lu T, Wu J, Shi G, He L, Zong H, Liu B and Zhu P: mcPGK1-dependent mitochondrial import of PGK1 promotes metabolic reprogramming and self-renewal of liver TICs. Nat Commun. 14:11212023. View Article : Google Scholar : PubMed/NCBI